NRx Pharmaceuticals (NRXP)
(Delayed Data from NSDQ)
$2.41 USD
+0.07 (2.99%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $2.41 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth D Momentum C VGM
Brokerage Reports
NRx Pharmaceuticals, Inc. [NRXP]
Reports for Purchase
Showing records 21 - 31 ( 31 total )
Company: NRx Pharmaceuticals, Inc.
Industry: Unclassified
Reports the Quarter - Funded to Key Catalyst
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: NRx Pharmaceuticals, Inc.
Industry: Unclassified
What is NRXP? What is the Need? Does it Work?
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: NRx Pharmaceuticals, Inc.
Industry: Unclassified
NRX-101 Could Change the Treatment Paradigm
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: NRx Pharmaceuticals, Inc.
Industry: Unclassified
This is the first time, to our knowledge, that patients with suicidal ideation have been welcomed in a clinical trial of an oral antidepressant.
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: NRx Pharmaceuticals, Inc.
Industry: Unclassified
Company: NRx Pharmaceuticals, Inc.
Industry: Unclassified
Buy Rating and $3.0 Price Target-INITIATION REPORT
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: NRx Pharmaceuticals, Inc.
Industry: Unclassified
DSMB Recommends Continuation of NRX-101 Phase 2 Trial; Reiterate Buy and $2.00 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: NRx Pharmaceuticals, Inc.
Industry: Unclassified
Alignment For NRX-101 Registration Manufacturing Reached With FDA; Reiterate Buy and $2.00 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: NRx Pharmaceuticals, Inc.
Industry: Unclassified
Momentum Growing With Focus on Advancing NRX-101; Reiterate Buy and $2 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: NRx Pharmaceuticals, Inc.
Industry: Unclassified
NRX-101 Continues to Make Progress in SSIB and ASIB; Reiterate Buy Rating and $2 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: NRx Pharmaceuticals, Inc.
Industry: Unclassified
Finding Synergies in Treatments for Bipolar Depression; Initiate at Buy With a $2 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V